Clinical Trial Update: Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial investigating rofecoxib with prolonged gemcitabine infusion in advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Rofecoxib (rofecoxib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Advanced Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: COMPLETED